Fig. 1

Purification and expansion of PαS MSC. Representative flow cytometry results of PαS MSC before (a) and after (b) cell sorting. Representative expansion kinetic of 3000 PαS MSC (n = 4) (c) and phase contrast micrographs of CFU-Fs 28 days after plating (d). T-cell inhibitory capacity of PαS MSC versus non-MSC control (“CD45^neg PαS^neg”: CD45^neg TER119^neg SCA-1^neg CD140a^neg) added to ovalbumin-pulsed DC in a CFSE T cell proliferation assay with OVA-TCR specific CD4+ T cells as described in the Methods section. Positive control are Ovalbumin-pulsed DC plus OVA-TCR specific CD4+ T cells and negative control are DC plus OVA-TCR specific CD4+ T cells without OVA (n = 3; (e). Representative phenotype of PαS MSC after in vitro expansion before intratracheal application after staining with isotype control (blue) and indicated mAbs (red; f). *p < 0.05, ***p < 0.001; data from n ≥ 4 (a-d), or n = 2 (e, f) experiments